A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy

Description

This research study is evaluating the impact a collaborative palliative care and oncology team will have on end-of-life outcomes, quality of end-of-life care, and the quality of life, symptoms, and mood of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy

Conditions

Acute Myeloid Leukemia, Myelodysplastic Syndromes

Talk to us

Study Overview

On this page

Study Details

Study overview

This research study is evaluating the impact a collaborative palliative care and oncology team will have on end-of-life outcomes, quality of end-of-life care, and the quality of life, symptoms, and mood of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy

Randomized Trial of a Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy

A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy

Condition
Acute Myeloid Leukemia
Intervention / Treatment

-

Contacts and Locations

Boston

Massachusetts General Hospital, Boston, Massachusetts, United States, 02114

Columbus

Ohio State University, Columbus, Ohio, United States, 43210

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients with AML receiving non-intensive therapy including hypomethylating agents, single-agent chemotherapy, targeted therapy agents, or single or combination non-intensive agents offered on a clinical trial, including the following populations:
  • * Newly diagnosed AML
  • * Relapsed AML
  • * Primary refractory AML
  • * The ability to provide informed consent
  • * The ability to comprehend English or complete questionnaires with minimal assistance of an interpreter
  • * Patients not receiving care at MGH
  • * Patients receiving intensive chemotherapy (requiring 4-6 week hospitalization)
  • * Patients receiving supportive care alone
  • * Major psychiatric illness or co-morbid conditions prohibiting compliance with study procedures
  • * Patients already receiving palliative care

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Massachusetts General Hospital,

Areej El-Jawahri, MD, PRINCIPAL_INVESTIGATOR, Massachusetts General Hospital

Study Record Dates

2024-12-01